PharmaMedic /
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
PharmaMedic
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us

#medicinesaccess

Tag

Windsor Framework measures start 1 January 2025

Windsor Framework measures start 1 January 2025

The government has announced that new measures laid out in the Windsor Framework regarding the supply of medicines to Northern Ireland will commence from 1 January 2025. This extends the previous deadline for compliance, which was 31 December 2023.

19 Jun 2023
Read More
EMA annual report reviews actions in 2022

EMA annual report reviews actions in 2022

The European Medicines Agency (EMA) has published its annual report for 2022, highlighting its challenges and successes in a year that saw it face ongoing and new public health emergencies.

24 May 2023
Read More
EC’s plans for updating pharma legislation unveiled

EC’s plans for updating pharma legislation unveiled

The European Commission’s (EC) long-awaited proposals for reforming pharma legislation have been published. The main thrust of the proposals is to create a single EU market for medicines to replace existing fragmentation and improve access for EU citizens.

11 May 2023
Read More
BIA calls on NICE to update evidence on rare disease medicines

BIA calls on NICE to update evidence on rare disease medicines

New research has found that the public believes a new approach should be adopted for making funding decisions about treatments for rare diseases. The report ‘Rare insights: examining the social values of treating rare diseases’, was commissioned by the UK BioIndustry Association’s (BIA) Rare Disease Industry Group (RDIG).

20 Apr 2023
Read More
Government confirms increase to pharma’s statutory scheme

Government confirms increase to pharma’s statutory scheme

Despite opposition from the Association of the British Pharmaceutical Industry (ABPI), the UK government has confirmed its plans to raise the revenue clawback rate paid by pharma for branded medicines under the statutory scheme by just over 3%, from 24.4% to 27.5% for 2023.

9 Mar 2023
Read More

Categories

  • Awards
  • Consultants
  • Events
  • News
    • General
    • Medical Affairs
    • Rare diseases
  • Our Services
  • Regulatory
  • Resources
    • White Paper

Tags

#ABPI #BIA #cancer #ClinicalTrials #drugapprovals #drugpricing #drugregulation #EC #EFPIA #EMA #EU #FDA #HorizonEurope #HTA #innovation #lifesciences #marketaccess #MDR #medicalaffairs #medicaldevice #medicinesaccess #medtech #mentalhealth #mhra #NHS #NICE #patients #pharmaregulation #pre-eclampsia #R&D #rarediseases #regulation #regulatory #research #startups #UKgovernment #ukpharma #ukregulation #VPAS AI Biotech COVID-19 Healthcare medicaldevices Pharma
PharmaMedic
  • Home
  • Join Us
  • Our Vision
  • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
Our Services
  • Start-Up
  • Product Launch
  • Product Development
Legal
  • Privacy Policy
  • Cookie Policy
Contact us
  • T:+44 (0) 208 168 1668
  • US Toll Free:+1 628 201 0911
  • [javascript protected email address]
  • The London Bioscience Innovation Centre (LBIC)
    2 Royal College Street
    London NW1 0NH

©2023 PharmaMedic. All Rights Reserved | Company Registration Number: 07364364 | VAT: 135986768

Powered by FL1 Digital